Sweden temporarily halts use of Janssen vaccine over blood clot concerns
Updated: 2021-04-15 10:03:37 KST
The Swedish Public Health Agency has put a hold on Johnson and Johnson's COVID-19 vaccine.
Wednesday's decision came a day after the drugmaker announced it will delay the rollout of its vaccine in Europe due to concerns over rare potential side effects that have been reported in the U.S.
So far, 31-thousand doses of the vaccine have arrived in Sweden, but none have yet been distributed.
The agency says it will await the conclusion of an ongoing probe by the European Medicines Agency, before making a final decision.
While some EU nations have put the vaccine on hold, France, Poland and Hungary say they will press ahead.
However, France is only approving its use to those 55 and older.
Also on Wednesday, Denmark became the first country in the world to completely halt use of the AstraZeneca vaccine over a reported link to a serious form of blood clot.
The decision pushes back the scheduled conclusion of the country's vaccination scheme to early August from July 25th.
However, the new timeline assumes it will use the Johnson and Johnson vaccine.
With many European countries temporarily halting use of the Janssen vaccine, Denmark could face a further delay.
With the AstraZeneca and Johnson and Johnson vaccines reporting rare cases of blood clots, the developers of Russia's Sputnik V vaccine said Wednesday that its shot does not cause blood clots.
According to the state-run research institute which developed the vaccine, a comprehensive analysis of adverse events during clinical trials and over the course of mass vaccinations showed no cases.
Like the Johnson and Johnson and AstraZeneca vaccines, Sputnik V uses adapted strains of the adenovirus that causes the common cold.
Lee Seung-jae, Arirang News.